[Alloy Therapeutics in Business Wire] Alloy Therapeutics expands executive team to strengthen therapeutic discovery and innovation for its partners
BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, announced expanded leadership to strengthen its portfolio of drug discovery capabilities and technologies for the global scientific community. Michael Schmidt, PhD has joined the company as its Chief Scientific Officer (CSO), where he will oversee technical innovation and ensure high scientific quality for Alloy’s broad portfolio of platforms, services, and venture studio company creation. Alloy has promoted Martin Leach, PhD, MBA to Chief Operating Officer (COO), from his previous position of Alloy Senior Vice President of Global Informatics and COO of its Daedamab research facility. Read...
Read More